Screener
SG&A at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Theravance Biopharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056760
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total revenues | 17,699 | 15,388 |
| Expenses: | ||
| Research and development (1) | 5,829 | 11,452 |
| Selling, general and administrative (1) | 17,720 | 18,370 |
| Restructuring expenses (1) (2) | 3,633 | — |
| Total expenses | 27,182 | 29,822 |
| Loss from operations | (9,483) | (14,434) |
| Interest expense (non-cash) | — | (643) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's SG&A?
- Theravance Biopharma (TBPH) reported SG&A of $17.72M in Q1 2026.
- How has Theravance Biopharma's SG&A changed year-over-year?
- Theravance Biopharma's SG&A decreased by 3.5% year-over-year, from $18.37M to $17.72M.
- What is the long-term trend for Theravance Biopharma's SG&A?
- Over 4 years (2021 to 2025), Theravance Biopharma's SG&A has grown at a -7.2% compound annual growth rate (CAGR), from $99.3M to $73.65M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Theravance Biopharma's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude